Intravitreal triamcinolone for refractory diabetic macular edema.

By A. Martidis, J. Duker, P. Greenberg, Adam H. Rogers, C. Puliafito, E. Reichel, C. Baumal. Ophthalmology (Rochester, Minn.), 2002

1,035 citations recorded by the source corpus.

Subfields: Ophthalmology

View Paper: https://www.semanticscholar.org/paper/7f896cf726882e9168a7e52a483c714ba70b4bda

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ophthalmology

1. N. Bhagat
2. R. Grigorian
3. A. Tutela
4. M. Zarbin

Citations in the corpus

• Diabetic macular edema: pathogenesis and treatment. (2009, background): “The existence of substantial group of patients with DME whose vision has failed to improve following laser photocoagulation has prompted clinicians to seek more effective treatment modalities.(176,205,218) The clinical outcomes and complications of intravitreal corticosteroid injection have been des”
• Müller cells in the healthy and diseased retina. (2010, background): “The anti-inflammatory glucocorticoid, triamcinolone acetonide, is commonly used clinically for the rapid resolution of diabetic macular edema (Martidis et al., 2002; Jonas et al., 2003).”